ISSCA Portugal 2026 | April 10–11, 2026 | Hotel Cascais Miragem, Lisboa / Cascais
Lisbon, Portugal — The International Society for Stem Cell Application (ISSCA) announces the International Congress in Regenerative Medicine – ISSCA Portugal 2026, taking place April 10–11, 2026, at the prestigious Hotel Cascais Miragem. As Europe continues to accelerate its interest in longevity, preventive care, and biologically informed medicine, Portugal is emerging as a key destination for innovation. ISSCA’s arrival marks a pivotal milestone in expanding scientific education, clinical safety, and global collaboration across the country’s growing regenerative medicine community.
The two-day conference will gather global leaders, European clinicians, and science-driven innovators to explore the technologies and clinical frameworks expected to define the next decade of regenerative and peptide-based medicine.
“Portugal has become a reference point in Europe for innovation and longevity medicine. ISSCA is here to strengthen that momentum by offering a global platform where clinicians can access the latest scientific standards in regenerative and peptide therapies.”
— Benito Novas, Founder of ISSCA
A Scientific Program Designed for Europe’s New Era of Regenerative Medicine
Portugal has experienced rapid growth in wellness, longevity clinics, preventive health, and minimally invasive procedures. Yet the adoption of advanced regenerative therapies still requires structured education and internationally validated standards.
ISSCA Portugal 2026 will introduce a scientific program focused on:
- Advanced regenerative medicine protocols and cellular science
- Clinical implementation of bioactive peptides for longevity, metabolism & immune modulation
- Regenerative aesthetics and tissue optimization
- Integrative approaches to inflammation, pain, and functional restoration
- Emerging evidence in musculoskeletal repair & performance medicine
Confirmed speakers include:
- Benito Novas (USA) – Opening Remarks & Global Strategic Vision
- Andrea Lapeire (Argentina) – Functional Restoration, Longevity & Regenerative Aesthetics
- Lauren Fitzgerald (USA) – Integrative Longevity & Hormonal Optimization
- Dr. Marcio Kume (Brazil) – Musculoskeletal Regeneration & Combined Cellular Therapies
- Prof. Dr. Roni Moya (Portugal) – European Leader in Regenerative Aesthetics, Exosomes & Facial Tissue Optimization
Additional expert faculty will be announced.
International Certifications Offered in Portugal
ISSCA Certification in Peptide Therapy & Regenerative Medicine
ISSCA Portugal will offer an expanded certification experience led by two of the most influential voices in regenerative aesthetics today:
- Prof. Dr. Roni Moya (Portugal) — European leader in regenerative aesthetics, exosomes, hair & skin regeneration
- Dr. Andrea Lapeire (Argentina) — Expert in functional longevity, metabolic restoration & regenerative protocols
Together, they will deliver a comprehensive, clinically structured certification that blends:
- Advanced aesthetic regeneration
- Exosome and peptide integration
- Tissue optimization protocols
- Longevity-focused clinical applications
- Evidence-based approaches for safe clinical implementation
This collaborative instruction represents a landmark moment for ISSCA in Europe, merging Latin American and European expertise into a unique, high-level educational experience.
MedConnect Portugal: A European Space for Strategic Collaboration
MedConnect Portugal will create a sophisticated environment where European and international physicians can build strategic collaborations, exchange high-level clinical insights, and explore emerging opportunities in longevity, regenerative medicine, and innovation-driven healthcare.
Attendees will be able to:
- Connect with leaders in Europe, North America, and Latin America
- Join scientific conversations that shape the future of the field
- Identify collaborative research or clinical opportunities
- Expand their professional network within a global medical community
MedConnect is one of ISSCA’s most valued components, reinforcing the organization’s mission to accelerate global medical collaboration.
Why ISSCA’s Arrival Matters for Portugal
Portugal is quickly positioning itself as one of Europe’s most dynamic destinations for wellness, longevity, and advanced clinical care. However, as regenerative and peptide medicine evolve, clinicians require structured training, evidence-based protocols, and international validation to meet both patient demands and European regulatory expectations.
ISSCA’s arrival matters because it:
- Introduces global scientific standards to Portugal’s clinical community
- Strengthens patient safety through structured, protocol-driven education
- Supports the country’s growing longevity and wellness ecosystem
- Connects Portuguese clinicians to ISSCA’s international faculty and research network
- Positions Portugal as a European hub for regenerative and peptide medicine
- Encourages scientific collaboration between Europe, Latin America, and the USA
ISSCA Portugal 2026 is designed not only to educate—but to empower Portugal to lead in Europe’s next chapter of biomedical innovation.
Call to Action: Registration Now Open
👉 Register Now at: https://issca.com
Benefits include:
- Early-Bird pricing
- Priority access to certification seats
- Admission to MedConnect Portugal
- Access to pre-event webinars and educational materials
About ISSCA
“The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.”
About Global Stem Cells Group
“Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.”
Safe Harbor Statement
Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business, partly based on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
